Crossmark

Neoadjuvant anthracycline-free versus anthracycline-containing chemotherapy combined with dual HER2 blockade in HER2-positive breast cancer: a real-world comparative study

Crossref DOI link: https://doi.org/10.1186/s13058-026-02312-w

Published Online: 2026-05-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Buyukkuscu, Asli

Isleyen, Zehra Sucuoglu

Ekinci, Omer Burak

Atasever, Tugay

Akkaya, Kubra

Aydin, Okan

Kulduk, Gamze

Celik, Emir

Erturk, Kayhan

Atci, M. Mustafa
License Information

Text and Data Mining valid from 2026-05-28

Version of Record valid from 2026-07-27
More Information

Article History

Received: 17 January 2026

Accepted: 18 May 2026

First Online: 28 May 2026

Declarations

Ethical approval and consent to participate: This retrospective study was approved by the Ethics Committee of Prof. Dr. Cemil Taşçıoğlu City Hospital. (Approval No: E-48670771-514.99-286278766). Ethics approval was obtained prior to data analysis.

Consent for publication: Not applicable.

Competing interests: The authors declare no competing interests.

Document is current

Any future updates will be listed below